In this pre-specified subanalysis of the SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) trial, which examined the effects of nebivolol in elderly heart failure (HF) patients, we explored the effects of left ventricular ejection fraction (EF) on outcomes, including the subgroups impaired EF (Յ35%) and preserved EF (Ͼ35%).
Despite many advances in its management, current largescale studies of patients with chronic heart failure (HF) indicate that this syndrome still carries a high morbidity and mortality (1, 2) . Although most large HF studies in the past were conducted in patients with an impaired systolic function and low left ventricular ejection fraction (LVEF), there has been an increased awareness in recent years that many patients with symptomatic HF have a (relatively) normal or preserved ejection fraction (EF) (3) . Indeed, the prevalence of HF patients with a preserved EF seems to have increased in the last 15 years (4), which is in part related to the aging of the population in the Western world. In terms of survival, patients with HF and preserved EF were previously assumed to have a better outcome, but recent data indicate that survival may be as poor as in patients with a low EF (5) .
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For these reasons, HF with preserved EF has received increasing attention in the last 5 to 10 years (6) , and several clinical trials have recently reported their results (7) (8) (9) . Findings from these studies show that neither the angiotensin-converting enzyme (ACE) inhibitor perindopril (8) nor the angiotensin receptor blocker (ARB) candesartan (7, 9) caused a statistically significant reduction in their primary end point, that is, a composite of morbidity and mortality. The use of digoxin is also not associated with a beneficial effect in this population (10) . In the recent HF Guidelines of the European Society of Cardiology, the high prevalence (Ͼ50%) and increasing importance of HF with preserved EF are clearly recognized (11) , but it is also acknowledged that no treatment for this patient category has yet been shown convincingly to reduce morbidity and mortality. Although some, albeit not conclusive, data are therefore available for ACE inhibitors and ARBs, no data of similar size regarding the value of beta-blockers in patients with HF and preserved EF are available (6) .
The SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) trial (12) investigated the role of the vasodilating beta-1 receptor antagonist nebivolol in elderly (age Ն70 years) patients with HF and showed evidence of benefit on the composite outcome of death or cardiovascular (CV) hospitalization (hazard ratio [HR]: 0.86; 95% confidence interval [CI]: 0.74 to 0.99 for the comparison of nebivolol with placebo, p ϭ 0.04). Approximately one-third of the patients in the SENIORS trial had an EF Ͼ35%. Given that there is very little randomized information about the effects of any beta-blocker in (elderly) patients with HF and in those with preserved systolic function, we undertook further pre-specified analyses of the SENIORS trial data to compare patients with decreased EF (Յ35%) with those with (relatively) preserved EF (Ͼ35%), that is, to examine the effect of beta-blockade with nebivolol in these 2 groups and also to compare the effect by exploring the interaction of EF with outcome.
Methods
The methods and main results of the SENIORS trial have been published previously (12) . SENIORS was a parallelgroup, randomized, double-blind, multicenter, international trial comparing nebivolol with placebo in elderly patients with HF on optimal standard therapy. To be eligible, patients had to be age Ն70 years, provide written informed consent, and have a clinical history of chronic HF with at least 1 of the following features: documented hospital admission within the previous 12 months with a discharge diagnosis of congestive HF or documented LVEF Յ35% within the previous 6 months. The main exclusion criteria were any recent change in CV drug therapy, contraindications to beta-blockers, and significant hepatic or renal dysfunction. Study medication was titrated over a 16-week period from a starting dose of 1.25 mg daily to a target of 10 mg daily. The primary outcome was the composite of all-cause mortality or hospital admissions for a CV cause, and the main secondary outcome was all-cause mortality. Baseline EF was measured by echocardiography in 94%, nuclear imaging in 4%, and magnetic resonance imaging in 2% of patients.
In a subset of patients, echocardiographic measurements were not only taken at baseline, but also after 12 months. These measurements included: EF, left ventricular (LV) endsystolic and -diastolic dimensions, and fractional shortening. Statistical methods. The influence of EF on the effects of nebivolol in the SENIORS trial population was measured as a dependent variable. Continuous variables were compared between groups using a t test or analysis of variance as appropriate. Categorical variables were compared using a chi-square test. The categories were pre-specified as less than or equal to or greater than the median of 35% for EF. In an additional analysis, we also studied 4 groups of EF, investigating patients with EF Յ30%, 31% to 35%, 36% to 46%, and Ͼ46% (30% was the median for the impaired EF group, and 46% was the median for the preserved EF group). A Cox proportional hazards model was used to assess the influence of EF with other baseline characteristics (prior myocardial infarction, history of coronary artery disease, age, male sex, diabetes, atrial fibrillation, New York Heart Association functional class, hypertension, systolic blood pressure, and heart rate) to explore any interaction of these variables on outcomes using the original randomized assignment of nebivolol versus placebo. The primary outcome of interest was the composite of all-cause mortality or CV hospital admission (time to first event), and the secondary outcome was all-cause mortality. Other exploratory outcomes, including CV hospitalization as the other component of the primary outcome, are also presented where considered appropriate. We used an intention-to-treat analysis throughout. Ethics of protocol. The authors confirm that this study complies with the Declaration of Helsinki, the locally ap- Cerebrovascular accident in the previous 3 months pointed ethics committees have approved the research protocol, and informed consent has been obtained from the participants.
Results
The SENIORS trial enrolled 2,128 patients age Ն70 years with stable HF. The EF measurement at baseline was available in all but 17 patients, and therefore the present study consisted of 2,111 patients. Mean EF in the whole population was 36% (median EF 33%), and about one-third of patients had an EF Ͼ35%. Baseline characteristics for patients with an EF Յ35% (mean 28.7%) or Ͼ35% (mean 49.2%) are shown in Table 1 . As expected, patients with an EF Ͼ35% were more often women, had a better functional class according to the New York Heart Association classification, had a higher blood pressure, and had hypertension more often and coronary artery disease less often in their medical history. Use of background medication was also slightly different between the groups. ACE inhibitors were used by Ͼ80% of patients in both groups, but ARBs (5.6% vs. 9.9%) and particularly aldosterone antagonists (5.6% vs. 32.1%) were used by fewer patients with relatively preserved EF, as compared with HF patients with impaired EF. There was no significant difference between the nebivolol dose achieved in the high and low EF groups (7.6 Ϯ 3.7 mg vs. 7.4 Ϯ 3.5 mg, respectively, p ϭ 0.398). During the study, drop-in use of beta-blockers was extremely low (Ͻ1%); drop-out rates, however, were significant (around 25%, similar in nebivolol and placebo groups), but there were no significant differences between the 2 EF groups. Influence of EF on outcome. The relationship between EF and the primary end point of all-cause death or CV hospitalization is shown in Figure 1 . In HF patients with EF Յ35%, the HR for nebivolol versus placebo was 0.86 (95% CI: 0.72 to 1.04, p ϭ 0.117), and in patients with EF Ͼ35% the HR was 0.81 (95% CI: 0.63 to 1.04, p ϭ 0.104); the p value for subgroup interaction was p ϭ 0.720, that is, there was no difference in the effect of nebivolol versus placebo between the 2 EF groups ( Table 2 ). In addition, the p value for interaction between the impaired (EF Յ35%) and preserved (EF Ͼ35%) groups were not significant for any of the secondary end points comparing nebivolol versus placebo (all values p Ͼ 0.48).
Results for the 4 EF groups for the primary and secondary end points showed overall similar results across the 4 subcategories. For the primary end point, the HRs in these 4 EF subgroups were: for patients with EF Յ30%, 0.81 (95% CI: 0.64 to 1.03); for patients with EF 31% to 35%, 0.92 (95% CI: 0.69 to 1.22); for patients with EF 36% to 46%, 0.84 (95% CI: 0.59 to 1.20); and for patients with EF Ͼ46%, 0.76 (95% CI: 0.52 to 1.11).
There was no significant interaction between treatment effect and EF when the latter was taken as a continuous variable (p ϭ 0.720). For the secondary end points, none of the p values for interaction were statistically significant ( Table 2) .
Results of the multivariate analysis showed that the effect of nebivolol was not significantly affected regarding the Nebivolol in Impaired and Preserved EF primary outcome. This was the case when EF was entered as a continuous variable, and also when using the 35% cutoff. No secondary outcomes showed nebivolol to have a statistically significant effect (p Ͼ 0.400 in all cases). Additional post-hoc analyses. Additional exploratory post-hoc analyses were conducted to investigate specific questions. Although we used 35% as a cutoff for preserved versus impaired EF (based on main study) (11) , an EF of 40% is also often used. We thus investigated the effect of nebivolol versus placebo in 643 patients with LVEF Ն40% (Table 3) . Results for both the primary outcome (HR: 0.82) as well as the secondary end points (only main secondary outcomes shown) were similar to those with EF Ն35%.
Continued
We also explored the influence of baseline heart rate on the subsequent effect of the beta-blocker (Table 4 ). The net reduction in heart rate by nebivolol (vs. placebo) in the whole population was 8.8 beats/min. This reduction was observed both in patients with impaired EF (net effect vs. placebo Ϫ9.7 beats/min) and in patients with preserved EF (net effect vs. placebo Ϫ6.9 beats/min) (both p Ͻ 0.001). For the whole population, there was no apparent influence of baseline heart rate (HRs for heart rate Յ80 and Ͼ80 beats/min: 0.85 and 0.83, respectively). In patients with EF Յ35%, the effect of nebivolol was larger in patients with higher than in those with lower heart rates (HR: 0.77 vs. 0.93), but in patients with an EF Ͼ35%, the reverse was observed (HR: 0.98 vs. 0.71). None of these interactions were statistically significant (Table 4 ). We also explored a possible association between the effect of nebivolol on blood pressure and outcome parameters in the 2 groups, but we could not find such an association. Measure of LV function and changes over time. In approximately 1,500 patients, echocardiographic measurements were performed at baseline and after 12 months. Table 5 shows these measures of LV function for the whole group as well as for patients with EF Յ35% and Ͼ35%. Overall, nebivolol had a significant effect on LV end-systolic dimension (mean change Ϫ0.18 cm on nebivolol vs. Ϫ0.10 cm on placebo, difference p ϭ 0.013) and on LVEF (change ϩ4.9% on nebivolol. vs. ϩ3.2% on placebo, p ϭ 0.002), whereas no effect was observed for LV end-diastolic dimension and a borderline significant difference for fractional shortening.
When the groups were analyzed according to their baseline EF, changes over time were overall more pronounced in patients with EF Յ35% than in those with EF Ͼ35%, but the effect between nebivolol and placebo was in general similar in the 2 groups. In both groups, a significant difference on EF favoring nebivolol was observed (p ϭ 0.013 and p ϭ 0.027, respectively).
Discussion
The main finding of the present study is that the effect of the beta-blocker nebivolol seemed to be of similar magnitude between HF patients with impaired EF and patients with preserved EF. Although the SENIORS trial was not powered to show a statistically significant effect of nebivolol in the EF subgroups, the HRs are similar with no apparent evidence of interaction in any subgroup analysis, which supports the hypothesis that there is a similar beneficial effect in patients with impaired and preserved EF.
Beta-blockers are standard drugs for patients with HF and decreased EF (11) , and together with ACE inhibitors and ARBs, they form the cornerstone of its treatment. Although Ͼ10,000 HF patients with EF Յ35% have been studied in large outcome trials, it is surprising that no larger trial has examined the effect of beta-blockade in patients with EF Ͼ35%. Given this absence of supportive data, Figure 1 Kaplan-Meier Curve of Primary Outcome
Kaplan-Meier curve of primary outcome (all-cause mortality or cardiovascular hospitalization) for impaired (Յ35%) and preserved (Ͼ35%) ejection fraction (EF) group for nebivolol (dotted line) versus placebo (solid line).
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current HF guidelines do not advocate the use of betablockers in these patients, but nevertheless, these drugs are used frequently in this population (13, 14) . In an Italian Registry study (13) , beta-blockers were used more in HF patients with preserved EF than in impaired EF, and a recent study from the U.S. showed that beta-blockers were used in Ͼ60% of patients with EF Ͼ40% (14) . Despite this apparent rather widespread use of betablockers in HF patients with (relatively) preserved EF, only a few data from smaller studies are available to support this strategy. Aronow et al. (15) examined the effect of propranolol in 158 older patients with HF and LVEF Ն40%, and found a reduction of mortality from 76% to 56%. Bergström et al. (16) investigated 113 patients with HF, an LVEF Ն45%, and echocardiographic evidence of diastolic dysfunction, but observed no effect of carvedilol on clinical end points. In another comparative study in only 26 patients with "diastolic HF" (LVEF Ͼ50%) (17), nebivolol was associated with a greater improvement of invasive hemodynamics than atenolol, but the effect on exercise parameters was similar. One larger study is the J-DHF (Japanese Diastolic Heart Failure Study) study, which plans to evaluate the effect of carvedilol in 800 HF patients with preserved EF (18) . Apart from these randomized studies, observational data also support the use of beta-blockers in HF patients with a normal EF (19, 20) .
The present study examined the effect of nebivolol on clinical end points in HF patients with impaired and preserved EF, and provides only limited information on mechanisms. One factor that may be associated with a better outcome in HF is the achieved dose of a betablocker, as shown in the SENIORS trial (21) . Patients with EF Ͼ35% had a higher blood pressure than those with EF Յ35%, and blood pressure is one of the most powerful parameters for predicting tolerability (21, 22) . In the SENIORS trial, patients with higher EF were not getting higher doses of nebivolol (21), so dose probably did not play a role. It has also been assumed that patients with a higher heart rate at baseline would benefit more from betablockade, but 2 recent studies of HF patients with impaired EF did not confirm this (23, 24) . In HF patients with preserved EF, baseline heart rate may theoretically be more relevant (25) , given the effect of slowing heart rate on increased diastolic filling, and one small study with the Effect of Baseline Heart Rate (<80 or >80 Beats/Min) on the Primary Outcome (All-Cause Mortality or Cardiovascular Hospitalizations) Table 4 Effect of Baseline Heart Rate (<80 or >80 Beats/Min) on the Primary Outcome Primary and Main Secondary Outcomes (Time to First Event) for High and Low EF LVEF ϭ left ventricular ejection fraction; other abbreviations as in Table 2 .
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Nebivolol in Impaired and Preserved EF calcium antagonist verapamil confirmed this (26) . The present data from the SENIORS trial do not support this concept, however. Direct improvement of LV function may be a third potential mechanism by which nebivolol might exert a beneficial effect in HF patients. In the present study, EF slightly increased in both groups, but it is unclear whether this effect was associated with the clinical findings. In a previous, more detailed (but smaller) echocardiographic substudy from the SENIORS trial, nebivolol was not found to have a beneficial effect on diastolic function parameters such as E/A ratio and E-wave deceleration time (27) .
Nevertheless, ischemia (particularly in the subendocardium) probably plays an important role in the pathophysiology of HF (28) , which may be even more prominent in patients with preserved EF (with or without LV hypertrophy) (29) . Beta-blockade may improve diastolic filling, thereby enhancing perfusion and metabolism (30) . The increased nitric oxide release, specifically induced by nebivolol, may cause an additional improvement of early relaxation (31, 32) . Consequently, a reduction of (subendocardial) ischemia by nebivolol in the present study is a potential mechanism for explaining the clinical effect.
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